Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Y-Biologics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions involve 2 distinct examiners and 2 distinct art units. MELCHIOR, JAMES RYLAND is the busiest examiner, with 1 busiest examiner pending action. The distribution of 2 pending office actions across 2 distinct art units indicates that the company's current patenting efforts touch upon different sub-specialties within Biotechnology & Pharmaceuticals.
Having 2 distinct examiners means the company is receiving feedback from multiple sources at the USPTO. This requires a prosecution strategy that can adapt to the specific requirements of 2 distinct examiners. The presence of 2 distinct art units suggests that the intellectual property is not confined to a single narrow classification. MELCHIOR, JAMES RYLAND manages 1 busiest examiner pending action, which represents a portion of the current pending workload. This level of diversity in the portfolio necessitates careful coordination across different examination groups. The 2 pending office actions provide a baseline for the company's current engagement with the patent office.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | PUTTLITZ, KARL J | 219d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | PUTTLITZ, KARL J | 219d overdue |
| 18280068 | ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF | MELCHIOR, JAMES RYLAND | 13d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280068 | ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF | MELCHIOR, JAMES RYLAND | 1644 | §112 | Non-Final OA | 13d | Pending | Sep 01, 2023 |
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | PUTTLITZ, KARL J | 1646 | §103§112Other | Non-Final OA | 219d overdue | Pending | Nov 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial